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Introduction
Proton-pump inhibitors (PPIs) are commonly 
prescribed for several acid-related disorders,1 
such as gastroesophageal reflux disease (GORD) 
and peptic ulcer disease.2–5 These drugs are also 
effective in treating ulcers associated with the use 
of nonsteroidal anti-inflammatory drugs 
(NSAIDs) and as prophylactic treatment for 
patients on NSAIDs and low-dose aspirin.6–10 
Recommended doses and duration of PPI treat-
ment vary by indications. Clinical guidelines 
rarely recommend PPI treatment for more than 
8–12 weeks.11,12 High-dose treatment is recom-
mended when initiating therapy for GORD and 
peptic ulcer disease, while low-dose treatment is 
generally regarded as a maintenance therapy for 
recovering patients.12
PPIs are generally considered safe.13 However, 
their use has been associated with increased risks 
of adverse events, such as bone fractures,14 kidney 
disease,15 microscopic colitis,16 and hypomagne-
semia.17 Use of PPIs has also been suggested to 
cause changes in the composition of the intestinal 
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Abstract
Background: The use of proton-pump inhibitors (PPIs) has grown worldwide, and there 
are concerns about increased unsubstantiated long-term use. The aim of the study was to 
describe the real-world use of PPIs over the past decade in an entire national population.
Methods: This was a nationwide population-based drug-utilization study. Patterns of 
outpatient PPI use among adults in Iceland between 2003 and 2015 were investigated, 
including annual incidence and prevalence, duration of use, and dose of tablet used (lower 
versus higher), as well as the proportion of PPI use attributable to gastroprotection.
Results: We observed 1,372,790 prescription fills over the entire study period, of which 95% 
were for higher-dose PPIs. Annual incidence remained stable across time (3.3–4.1 per 100 
persons per year), while the annual prevalence increased from 8.5 per 100 persons to 15.5 per 
100 persons. Prevalence increased with patient age and was higher among women than men. 
Duration of treatment increased with patients’ age (36% of users over 80 years remained on 
treatment after 1 year compared with 13% of users aged 19–39 years), and was longer among 
those initiating on a higher dose compared with a lower dose. The proportion of PPI users 
concurrently using nonsteroidal anti-inflammatory drugs decreased over the study period, 
while the proportion concurrently using acetylsalicylic acid, oral anticoagulants, or platelet 
inhibitors increased.
Conclusions: In this nationwide study, a considerable increase in overall outpatient use of 
PPIs over a 13-year period was observed, particularly among older adults. Patients were 
increasingly treated for longer durations than recommended by clinical guidelines and mainly 
with higher doses.
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microbiota, increasing the risk of Clostridium dif-
ficile infection18 and chronic liver disease.19 
Although PPIs have been shown to minimize 
NSAID-related adverse effects in the stomach, 
recent evidence suggests that PPIs might cause 
changes in the composition of the small intestinal 
microbiota, augmenting unwanted adverse effects 
of NSAIDs in the small intestines.20 Furthermore, 
discontinuation of PPI treatment has been linked 
to acid hypersecretion21 and the development of 
dyspeptic symptoms in healthy volunteers.22
PPIs have had undisputed effects on the treatment 
of symptoms related to excessive acid secretion, 
but concerns are growing about inappropriate 
indications and potential overuse, both within hos-
pitals and in the primary-care setting.23–26 These 
concerns are compounded by observations of 
increased long-term use especially in elderly popu-
lations,27–29 where overprescribing has been associ-
ated with increased morbidity and mortality.30
In light of these concerns, we aimed to provide 
data on real-world use of PPIs, and changes 
thereof, across the past decade in an entire 
national population. Specifically, we aimed to 
determine patterns of use by patient and pre-
scriber characteristics, including treatment dura-
tion contrasting between higher- and lower-dose 
PPIs. Furthermore, we described the proportion 
of PPI use attributable to gastroprotection.
Methods
This was an observational drug-utilization study 
describing the use of PPIs among the adult 
Icelandic population (19 years or older) during 
the period 1 January 2003 through to 31 
December 2015.
Data sources
The Icelandic Medicines Registry (IMR) contains 
individual information on all dispensed prescrip-
tion drugs in outpatient care in Iceland since 1 
January 2003. We received information from the 
IMR on PPI dispensing during the study period. 
As of 2010, the IMR also contained information 
on dispensed prescription drugs within nursing 
homes in Iceland.31,32 Completeness of the IMR 
ranged from 91% to 98% of all dispensed pre-
scription drugs for the study years. Information on 
wholesale statistics of PPIs was provided by the 
Icelandic Medicines Agency.33
The Icelandic Population Register provided 
information about all citizens, Icelandic and for-
eign, residing in Iceland during the study period, 
including data on month and year of birth, sex, 
residency at 1 January 2003, migration status, 
and date of death (if appropriate).
Using personal identification numbers, unique to 
every individual residing in Iceland, we linked 
together the variables from these two registries.
Study drugs
The drugs of interest were classified according to 
the World Health Organization anatomical thera-
peutic chemical/defined daily doses (ATC/DDD) 
classification.34 During the study period, four PPI 
substances were prescribed in Iceland: omeprazole 
(A02BC01), lansoprazole (A02BC03), rabepra-
zole (A02BC04), and esomeprazole (A02BC05). 
We further categorized each PPI type by available 
tablet strengths in milligrams as higher or lower 
dose. In the National Institute for Health and Care 
Excellence (NICE) clinical guidelines, PPI doses 
(in mg) are defined as standard/full dose, double 
dose, or low dose.12 In the current study, standard 
and double doses were defined as higher-dose PPIs 
and low doses as lower-dose PPIs (Table 1).
On 1 February 2009, PPIs became available as 
over-the-counter (OTC) products in Iceland. 
However, the majority of PPIs during the study 
period were obtained by prescription rather than 
OTC, with OTC sales ranging from 1% in 2009 
to 10% in 2015 of the total dispensed DDDs in 
these years (Supplementary Table S1).
Information on the indication for the prescription 
of PPIs was not available in the IMR. We explored 
potential reasons for PPI use by assessing the pro-
portion of use attributable to gastroprotection, 
that is, concurrent use of PPIs with acetylsalicylic 
acid (ATC codes: B01AC06, N02BA01, 
B01AC30), NSAIDs (ATC codes: M01, exclud-
ing M01AX), oral anticoagulants (ATC codes: 
B01AA, B01AE, B01AF, B01AX06), and plate-
let inhibitors (B01AC04, B01AC07, B01AC22, 
B01AC24, B01AC30).
Analysis
We presented overall use of PPIs in Iceland as the 
total number of dispensed DDDs to the adult pop-
ulation stratified by calendar year, PPI substance, 
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and specialty of the prescribing physician (primary 
care, gastroenterology, and other specialties).
Annual prevalence (per 100 persons) of PPI use 
was defined as the number of adult individuals 
who filled at least one prescription in the relevant 
calendar year (2003–2015) divided by the total 
adult population residing in Iceland on 1 July of 
that year. Further we reported the sex- and age-
specific prevalence of PPI use in 2015, the last 
year of the study period (by 1-year age intervals 
between ages 19–39 years and 80+ years). As a 
sensitivity analysis, we repeated the analysis of 
annual prevalence requiring at least two filled PPI 
prescriptions in the relevant calendar year to be 
classified as a prevalent user.
Annual incidence (per 100 persons per year) of 
PPI use was defined as the number of adult indi-
viduals who, during the relevant calendar year 
(2005–2015), filled their first PPI prescription 
after a period of 24 months during which no PPI 
prescriptions were filled, divided by the total 
adult population residing in Iceland on 1 July of 
that year.
To describe the duration of PPI use we used the 
‘proportion of patients covered’ method, which 
estimates the proportion of subjects that are alive 
and covered by treatment on a given day after the 
initiation of an incidence treatment episode. For 
each patient, we estimated duration of each filled 
prescription based on days’ supply, assuming one 
tablet as a daily dose. We allowed for a grace 
period of 108 days (2 × the median number of 
days between dispensing, that is, the number of 
days by which 50% of the population had received 
a subsequent dispensing), to account for irregular 
prescription fills and added to the duration of 
each prescription. If a patient did not fill a new 
prescription within this time we considered them 
to have discontinued their PPI treatment. They 
could then later re-enter the user population upon 
initiating a new treatment episode. We followed 
incident PPI users for 5 years, from the date of 
their first PPI prescription (day 0), and calculated 
the proportion of patients covered by dividing the 
number of users that were using the drug at day X 
(defined by 30-day intervals) by the number of 
people who were still alive and had not migrated 
at day X. Furthermore, to assess differences in 
treatment duration by patient age or by their pre-
scribed PPI dose, we stratified the duration analy-
sis by age (19–39, 40–49, 50–59, 60–69, 70–79, 
80+ years), dose strength (higher versus lower), 
and sex. In addition, we explored the distribution 
in number of dispensed DDDs and tablets in the 
first 5 years after start of initial treatment episode 
(0–99, 100–199, 200–299, 300–399, 400–499, 
500–599, 600–699, 700–799, 800–899, 900–999, 
⩾ 1000).
To assess concurrent use of selected drugs (ATC 
codes: M01 [excluding M01AX], B01AC06, 
N02BA01, B01AC30, B01AA, B01AE, B01AF, 
B01AX06, B01AC04, B01AC07, B01AC22, 
B01AC24, and B01AC30), we calculated the 
proportion (%) of prevalent PPI users in each 
study year who also filled prescriptions for these 
drugs within 90 days leading up to a PPI prescrip-
tion fill. To assess the pattern of concurrent use 
among different age groups we performed a strati-
fied analysis by age (19–39, 40–64, 65+ years).
All analyses were performed using R version 3.4.235 
and RStudio.36 The study was approved by the 
National Bioethics Committee in Iceland (study 
reference number: VSNb2015080004/03.03). As 
the study was based on national registry data, we 
did not obtain informed consent from individuals 
Table 1. Proton-pump inhibitors and tablet strengths dispensed to adults in Iceland in 2003–2015.
PPI ATC DDD (mg) Lower dose (mg)* Higher dose (mg)*
Omeprazole A02BC01 20 10 20, 40
Lansoprazole A02BC03 30 15 30
Rabeprazole A02BC04 20 10 20
Esomeprazole A02BC05 30 10 20, 40
* National Institute for Health and Care Excellence clinical guidelines define PPI doses as standard/full dose, double dose 
or low dose.12 Here we categorize low PPI doses as lower-dose PPIs while standard and double doses are categorized as 
higher-dose PPIs. ATC, anatomical therapeutic chemical; DDD, defined daily dose, PPI, proton-pump inhibitor.
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in the study population. All personal information 
was encrypted and de-identified prior to analysis.
Results
We observed 1,372,790 prescription fills for PPIs 
over the entire study period. The vast majority 
(95%) were higher-dose prescriptions. Among 
313,296 individuals constituting our source pop-
ulation, a total of 101,909 (33%) filled at least 
one PPI prescription, including 56,252 women 
(55%) and 45,657 men (45%). The mean age at 
first prescription fill was 46 years (interquartile 
range 30–60). We observed a median of three PPI 
prescription fills per patient (interquartile range 
1–15). The median number of days between pre-
scription fills was 54.
During the study period, there was an increase in 
total PPI use, measured as the number of dis-
pensed DDDs, from 3.5 million DDDs dispensed 
in 2003 to 10.7 million DDDs dispensed in 2015 
(Figure 1a). Primary-care physicians prescribed 
the majority (60%) of all dispensed DDDs during 
the study period, whereas gastroenterologists pre-
scribed 11% and physicians of other specialties 
prescribed 29%. Prior to 2009, esomeprazole was 
the most commonly prescribed drug among all 
specialties. Although esomeprazole remained the 
PPI of choice among gastroenterologists, ome-
prazole became the most commonly prescribed 
PPI thereafter among nongastroenterologists 
(Figure 1b–d).
Figure 2 shows an increase in annual prevalence 
of PPI use with calendar time, from 8.5 per 100 
persons in 2003 to 15.5 per 100 persons in 2015. 
Meanwhile, the incidence of PPI use ranged from 
3.3 per 100 persons in 2005 to 4.1 per 100 per-
sons in 2015. A more stringent measure of annual 
prevalence, requiring at least two prescription fills 
within a relevant year, yielded a prevalence of 5.4 
per 100 persons in 2003 to 11.0 per 100 persons 
in 2015 (Supplementary Figure S1). Prevalence 
of PPI use was higher among women than men 
and increased with patient age (Figure 3).
We identified 74,973 incident PPI users in our 
study population, which we then followed for 5 
years to estimate the proportion of users still on 
treatment over time. Figure 4(a) shows the esti-
mated treatment duration stratified by patient 
age. The proportion of patients still on PPI treat-
ment after 1 year was highest among those over 
80 years of age, (36%) and lowest in those aged 
19–39 years (13%). After 5 years, the proportion 
was highest in those aged 70–79 years (20%) and 
lowest among the youngest, 19–39 years (7%). 
The majority of patients filled fewer than 200 
DDDs/tablets during the first 5 years after start-
ing PPI treatment (Supplementary Figure S2).
Figure 4(b) shows PPI treatment duration among 
incident PPI users stratified by strength of PPI 
dose at treatment initiation. Of the 74,973 inci-
dent users, 70,720 (94%) initiated on higher-dose 
PPIs and 4240 (6%) on lower-dose PPIs. The 
proportion of patients still treated with the same 
dose after 1 year was greater among those pre-
scribed higher- (21%) than lower-dose PPIs 
(9%). The proportion of patients still on the same 
dose was 13% versus 2% after 5 years, respectively 
on higher- versus lower-dose PPIs. Duration of 
treatment by PPI dose strength was nearly identi-
cal for both sexes (Supplementary Figure S3).
We observed a slight decrease in the proportion of 
PPI users concurrently using drugs that have 
been shown to be ulcerogenic or increase the risk 
of bleeding, from 38% in 2003 to 36% in 2015 
(Figure 5). The proportion of PPI users concur-
rently using NSAIDs decreased from 33% in 
2003 to 24% in 2015. We observed an increase in 
concurrent use of oral anticoagulants (3–6%), 
acetylsalicylic acid (5–8%), and other platelet 
inhibitors (2–3%). The proportion of PPI users 
concurrently treated with any of these four drugs 
was highest among those aged over 65 years (47% 
in 2003, 47% in 2015) and lowest among the 
youngest aged 19–39 years (21% in 2003, 17% in 
2015) (Supplementary Figure S4).
Discussion
In this study, which covered all PPI dispensing in 
an entire national population over 13 years, we 
observed widespread and increasing use of PPIs, 
especially among the elderly. Primary-care physi-
cians prescribed the vast majority of dispensed 
PPIs in our study data. While the number of new 
users remained relatively stable over time, the 
results suggested that patients were increasingly 
treated for longer durations than recommended 
by clinical guidelines and mainly with higher-dose 
PPIs.
The rising prevalence of PPI use across time 
observed in our study is in line with recently 
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Figure 2. Annual prevalence and incidence (per 100 persons) of proton-pump inhibitor use among adults in 
Iceland.
Figure 3. Age- and sex-specific prevalence of proton-pump inhibitor use among adults in Iceland in 2015.
published reports in comparable populations.27,29,37 
However, the prevalence in Iceland in 2015 was 
more than twice that observed among adults in 
Denmark in 2014 (15.5% versus 7.4%). GORD is 
the most common indication for PPIs with an esti-
mated prevalence of 9–26% in European popula-
tions.38 Although our use estimates were within 
this range, we were unable to draw definitive 
conclusions on the appropriateness of PPI use in 
Iceland as we did not have information on the indi-
cations for which PPIs were prescribed nor data on 
the prevalence of GORD or other underlying con-
ditions in the population.
Inappropriate use of PPIs in the outpatient set-
ting, for example, in the form of inappropriate 
ÓÖ Hálfdánarson, A Pottegård et al.
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Figure 4. Duration of PPI treatment among incident users: (a) by age; (b) by initial dose strength of the proton-
pump inhibitors (PPIs), measured as the proportion of patients covered.
indications and automatic renewal of prescrip-
tions without re-evaluation of patients’ symptoms, 
is a looming concern.25,39 Such concerns were 
reinforced by Reimer and Bytzer’s findings, which 
showed that only 27% of people receiving long-
term treatment had a verified diagnosis justifying 
the need for long-term treatment.40 The NICE 
clinical guidelines recommend long-term PPI 
therapy for rare conditions like Zollinger–Ellison 
syndrome or Barrett’s esophagus as well as for 
patients with severe esophagitis, who have not 
responded to an initial high-dose 8-week treat-
ment, and for patients who have experienced a 
dilation of an esophageal stricture.12 In general, 
the recommended duration of PPI treatment in 
clinical guidelines rarely exceeds 12 weeks. We 
found that 22% remained on treatment 1 year 
after treatment initiation. The proportion was 
highest among the oldest age group (36%) and 
lowest among the youngest (13%). Extended 
treatment durations among older adults are con-
cerning in light of widespread polypharmacy and 
increased risk of adverse events with PPI use.41 In 
fact, we observed that nearly half of older adults in 
our data used PPIs concurrently with NSAIDs, 
acetylsalicylic acid, oral anticoagulants, or platelet 
inhibitors, reflecting the level of polypharmacy 
among older adults using PPIs. Given the recent 
evidence of PPIs potentially facilitating injurious 
effects of NSAIDs in the small intestines, espe-
cially in older people and other high-risk patients,20 
this pattern of high concurrent drug use might be 
Therapeutic Advances in Gastroenterology 11
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concerning. However, as we were unable to link 
prescription data with clinical information, we 
cannot rule out that these patients were appropri-
ately prescribed PPIs as bleeding prophylaxis.
The vast majority of PPI users in our population 
initiated treatment with higher-dose PPIs and 
after 1 year 21% remained on that treatment, for 
example, had not switched to lower-dose PPIs or 
discontinued treatment. This might indicate that 
their underlying symptoms are more severe than 
among those initiating treatment on lower doses 
and reflect the level of difficulty some users expe-
rience when discontinuing treatment due to 
resurfacing symptoms.42
Recently, Helgadottir and colleagues demon-
strated that among confirmed GORD patients on 
long-term PPI treatment, women were more 
likely than men to be able to lower their dose by 
half, while still achieving symptom relief.43 In our 
study we found no observable difference in treat-
ment durations by patient sex, nor did women 
seem more likely to initiate or maintain treatment 
on lower-dose PPIs. Thus, it is conceivable that 
women might be able to tolerate lower PPI doses 
than is mostly used nowadays.
The present study has several limitations. First, as 
with all register-based drug studies, it is not cer-
tain that individuals who filled the PPI prescrip-
tions actually consumed the drugs. To address 
this, we performed a sensitivity analysis 
(Supplementary Figure S1) requiring at least two 
PPI prescription fills within a year to count as a 
prevalent PPI user, which resulted in lowered 
prevalence estimates. Actual consumption might 
thus in reality lie between these two measures of 
prevalence. Second, the study data did not con-
tain information on clinical characteristics such as 
indications underlying the PPI prescriptions and/
or the severity of symptoms, which prevented us 
from drawing sound conclusions on the appropri-
ateness of PPI prescribing in our population. 
Third, information on PPI use within nursing 
homes was not included in the IMR until 2010, 
Figure 5. Concurrent use of proton-pump inhibitors with drugs that are ulcerogenic or increase the risk of 
upper gastrointestinal bleeding. NSAIDs, nonsteroidal anti-inflammatory drugs.
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which presumably resulted in an underestimation 
of the prevalence of PPI use among the elderly in 
the first half of the study period. Fourth, informa-
tion on exact dosing for each prescription was not 
available in our data preventing us from accu-
rately assessing prescribed doses. Our assess-
ments of PPI doses were based on dispensed 
tablet strengths and therefore only an approxima-
tion of actual doses. Finally, PPIs became availa-
ble OTC on 1 February 2009. However, the 
proportion of PPIs sold OTC was relatively low, 
ranging from 1% to 10% of the total number of 
DDDs sold annually from 2009 to 2015, and may 
therefore only have led to a slight underestima-
tion of overall PPI use.
In conclusion, over a 13-year follow-up period we 
observed a considerable increase of real-world PPI 
use in a nationwide population setting, particu-
larly among older adults. We found that a number 
of patients stayed on PPI treatment for longer 
periods than is recommended by clinical guide-
lines, mainly on higher doses. In view of these 
results, further initiatives towards appropriate pre-
scribing of PPIs, especially in terms of the adop-
tion of de-prescribing strategies, are warranted.
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